MedTrace Logo

Pilot Study of RR-HNK in OCD

NCT06575075 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-03-05

No results posted yet for this study

Summary

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

RR-HNK/Hydroxynorketamine

(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

DRUG

Placebo

Sterile Saline

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Carolyn Rodriguez

    lead OTHER

Principal Investigators

  • Carolyn Rodriguez, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-23
Primary Completion
2028-11-30
Completion
2029-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06575075 on ClinicalTrials.gov